logo

For the Inventor, By the Inventor

Cardiff, United Kingdom

Verona Pharma Plc


USPTO Granted Patents = 17



Trademarks = 6

Forward Citations = 114

Loading Chart...
Loading Chart...

16 inventors (with patents filed for the assignee):

goldMedal Peter Lionel Spargo (9 out of 9 patents)

silverMedal Edward James French (6 out of 6 patents)

bronzeMedal Phillip A Haywood (4 out of 4 patents)

4.  Michael J A Walker (4 out of 16 patents)

5.  Julian Scott Northen (3 out of 31 patents)

6.  Mario Cazzola (3 out of 3 patents)

7.  Luigino Calzetta (3 out of 4 patents)

8.  Katharine Abbott-Banner (2 out of 2 patents)

9.  John Hanrahan (2 out of 2 patents)

10.  David Thomas (2 out of 2 patents)

11.  David Jack (2 out of 4 patents)

12.  Alexander W Oxford (2 out of 58 patents)

13.  John Mykytiuk (2 out of 6 patents)

14.  Kevin Stephen Turner (2 out of 2 patents)

15.  Philippe Fernandes (1 out of 11 patents)


17 patents:

1. 12409180 - Formulation production process (2025-09-09),
2. 12251384 - Particulate composition (2025-03-18),
3. 12194045 - Particulate composition (2025-01-14),
4. 12168011 - Formulation production process (2024-12-17),
5. 11759467 - Treatment (2023-09-19),
6. 11491155 - Salt of a pyrimido[6,1-A]isoquinolin-4-one compound (2022-11-08),
7. 10945950 - Liquid inhalation formulation comprising RPL554 (2021-03-16),
8. 10864213 - Treatment (2020-12-15),
9. 10710998 - Compound and process (2020-07-14),
10. 10471063 - Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist (2019-11-12),
11. 10463665 - Salt of a pyrimido[6,1-A]isoquinolin-4-one compound (2019-11-05),
12. 9956171 - Liquid inhalation formulation comprising RPL554 (2018-05-01),
13. 9717732 - Drug combination (2017-08-01),
14. 9700558 - Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist (2017-07-11),
15. 9062047 - Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound (2015-06-23),
Verona Pharma Plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of respiratory diseases. The company's lead drug candidate is RPL554, a first-in-class inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, intended for the treatment of COPD and cystic fibrosis. Verona Pharma is dedicated to improving the lives of people suffering from respiratory conditions through the development of safe and effective medications.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

17 Patents

#5 in Cardiff

#1,053 in United Kingdom

#34,861 in the World

...
Cardiff, United Kingdom

Verona Pharma Plc

Forward Citations = 114

16 inventors:

goldMedal Peter Lionel Spargo (9 out of 9 patents)

silverMedal Edward James French (6 out of 6 patents)

bronzeMedal Phillip A Haywood (4 out of 4 patents)

4.  Michael J A Walker (4 out of 16 patents)

5.  Julian Scott Northen (3 out of 31 patents)

Please report any incorrect information to support@idiyas.com
Loading…